Earlier investigations demonstrated that the amplification of RAD21 epigenetically restrains interferon signaling, thus promoting immune escape in ovarian cancer and having the potential to function as a molecular sign for immunotherapy regarding ovarian cancer (11). This evidence concerns the gene RAD21 and ovarian carcinoma.